Recent AUTL News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/27/2026 08:39:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 12:02:10 PM
- Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates • GlobeNewswire Inc. • 03/27/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 08:54:04 PM
- Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026 • GlobeNewswire Inc. • 03/16/2026 08:10:00 PM
- Autolus Therapeutics to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 02/24/2026 12:00:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/13/2026 09:07:51 PM
- The $71 Billion Cancer Shift: Why The FDA Is Speeding Up • GlobeNewswire Inc. • 02/05/2026 02:26:03 PM
- Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/04/2026 01:57:41 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/26/2026 09:09:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2026 09:07:48 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/12/2026 01:37:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 01:36:17 PM
- Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026 • GlobeNewswire Inc. • 01/12/2026 12:00:00 PM
- Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform • Business Wire • 01/06/2026 02:00:00 PM
- Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform • GlobeNewswire Inc. • 01/06/2026 02:00:00 PM
